| 中國醫藥大學 |
2007-10-06 |
CYP1A1基因多形性與吸菸和冠狀動脈心臟病發生之相關
|
郭李堂; 宋鴻樟(Fung-Chang Sung); 葉志清 |
| 國家衛生研究院 |
2013-07 |
CYP1A2 genetic polymorphisms are associated with early antidepressant escitalopram metabolism and adverse reactions
|
Kuo, HW;Liu, SC;Tsou, HH;Liu, SW;Lin, KM;Lu, SC;Hsiao, MC;Hsiao, CF;Liu, CY;Chen, CH;Lu, ML;Shen, WW;Tang, HS;Liu, SI;Chang, LH;Wu, HY;Chang, YS;Yeh, TK;Chen, AC;Liu, YL |
| 臺北醫學大學 |
2013 |
CYP1A2 genetic polymorphisms are associated with early antidepressant escitalopram metabolism and adverse reactions
|
HW, Kuo;SC, Liu;HH, Tsou;SW, Liu;KM, Lin;SC, Lu;MC, Hsiao;CF, Hsiao;CY, Liu;CH, Chen;ML, Lu;WW, Shen;HS, Tang;SI, Liu;LH, Chang;HY, Wu;Chang |
| 臺北醫學大學 |
2013 |
CYP1A2 genetic polymorphisms are associated with early antidepressant escitalopram metabolism and adverse reactions
|
Kuo, HW;Liu, SC;Tsou, HH;Liu, SW;Lin, KM;Lu, SC;Hsiao, MC;Hsiao, CF;Liu, CY;Chen, CH;Lu, ML;Shen, WW;Tang, HS;Liu, SI;Chang, LH;Wu, HY;Chang |
| 臺大學術典藏 |
2020-02-06T08:11:28Z |
CYP1A2 genetic polymorphisms are associated with early antidepressant escitalopram metabolism and adverse reactions
|
Kuo H.-W.;Liu S.C.;Tsou H.-H.;Liu S.-W.;Lin K.-M.;Shao-Chun Lu;Hsiao M.-C.;Hsiao C.-F.;Liu C.-Y.;Chen C.-H.;Lu M.-L.;Shen W.W.;Tang H.-S.;Liu S.-I.;Chang L.-H.;Wu H.-Y.;Chang Y.-S.;Yeh T.-K.;Chen A.C.;Liu Y.-L.; Kuo H.-W.; Liu S.C.; Tsou H.-H.; Liu S.-W.; Lin K.-M.; SHAO-CHUN LU; Hsiao M.-C.; Hsiao C.-F.; Liu C.-Y.; Chen C.-H.; Lu M.-L.; Shen W.W.; Tang H.-S.; Liu S.-I.; Chang L.-H.; Wu H.-Y.; Chang Y.-S.; Yeh T.-K.; Chen A.C.; Liu Y.-L. |
| 國家衛生研究院 |
2010-11 |
CYP1A2 genetic polymorphisms are associated with treatment response to the antidepressant paroxetine
|
Lin, KM;Tsou, HH;Tsai IJ;Hsiao, MC;Hsiao, CF;Liu CY;Shen, WW;Tang, HS;Fang, CK;Wu, CS;Lu, SC;Kuo, HW;Liu, SC;Chan, HW;Hsu, YT;Tian, JN;Liu, YL |
| 國立臺灣大學 |
2010 |
Cyp1a2 Genetic Polymorphisms Are Associated with Treatment Response to the Antidepressant Paroxetine
|
林克明; 鄒小蕙; 蕭美君; 蕭金福; 劉嘉逸; 沈武典; 湯華盛; 方俊凱; 吳其炘; 呂紹俊; 郭湘維; LIN, KEH-MING; TSOU, HSIAO-HUI; HSIAO, MEI-CHUN; HSIAO, CHIN-FU; LIU, CHIA-YIH; SHEN, WINSTON W.; TANG, HWA-SHENG; FANG, CHUN-KAI; WU, CHI-SHIN; LU, SHAO-CHUN; KUO, HSIANG-WEI; LIU, YU-LI |
| 中國醫藥大學 |
2010 |
CYP1A2 genetic polymorphisms are associated with treatment response to the antidepressant paroxetine
|
林克明(Keh-Ming Lin)*; 劉玉麗(Liu, Yu-Li)* |
| 臺大學術典藏 |
2020-02-06T08:11:29Z |
CYP1A2 genetic polymorphisms are associated with treatment response to the antidepressant paroxetine
|
Hsiao M.-C.; Hsiao C.-F.; Liu C.-Y.; Shen W.W.; Tang H.-S.; Fang C.-K.; Wu C.-S.; SHAO-CHUN LU; Kuo H.-W.; Liu S.C.; Chan H.-W.; Hsu Y.-T.; Tian J.-N.; Liu Y.-L.; Lin K.-M.;Tsou H.-H.;Tsai I.-J.;Hsiao M.-C.;Hsiao C.-F.;Liu C.-Y.;Shen W.W.;Tang H.-S.;Fang C.-K.;Wu C.-S.;Shao-Chun Lu;Kuo H.-W.;Liu S.C.;Chan H.-W.;Hsu Y.-T.;Tian J.-N.;Liu Y.-L.; Lin K.-M.; Tsou H.-H.; Tsai I.-J. |
| 臺大學術典藏 |
2010 |
CYP1A2 genetic polymorphisms are associated with treatment response to the antidepressant paroxetine
|
Lin K.-M.; Tsou H.-H.; Tsai I.-J.; Hsiao M.-C.; Hsiao C.-F.; Liu C.-Y.; Shen W.W.; Tang H.-S.; Fang C.-K.; CHI-SHIN WU; Lu S.-C.; Kuo H.-W.; Liu S.C.; Chan H.-W.; Hsu Y.-T.; Tian J.-N.; Liu Y.-L. |
| 國家衛生研究院 |
2012-03 |
CYP1A2 genetic polymorphisms associated with antidepressant escitalopram metabolism and adverse reactions at early stage
|
Liu, Y;Tian, J;Kuo, H;Tsou, H;Liu, S;Lu, S;Lin, K;Chen, Y |
| 國立中山大學 |
2013-07-23 |
CYP26B1 及相關蛋白質在檳榔引發口腔癌之研究
|
許正傑 |
| 高雄醫學大學 |
2012 |
CYP27A1 polymorphism 與有代謝症候群男性之脂肪激素和膽固醇代謝顯著相關
|
鄭凱鴻;劉家駒;黃俊農;李永進;朱志生;眭致遠;賴文德;黃書彬 |
| 高雄醫學大學 |
2012 |
CYP27A1 polymorphism 與有代謝症候群男性之脂肪激素和膽固醇代謝顯著相關
|
鄭凱鴻;劉家駒;黃俊農;李永進;朱志生;眭致遠;賴文德;黃書彬 |
| 臺北醫學大學 |
2004 |
CYP2B1/2 contributes to propofol metabolism to 4-hydroxy-propofol in rat liver.
|
陳瑞明; Lin YL; Chen TL; Chen RM; |
| 國家衛生研究院 |
2011-08 |
CYP2B6 polymorphisms influence the plasma concentration and clearance of the methadone S-enantiomer
|
Wang, SC;Ho, IK;Tsou, HH;Tian, JN;Hsiao, CF;Chen, CH;Tan, HK;Lin, L;Wu, CS;Su, LW;Huang, CL;Yang, YH;Liu, ML;Lin, KM;Chen, CY;Liu, SC;Wu, HY;Chan, HW;Tsai, MH;Lin, PS;Liu, YL |
| 中國醫藥大學 |
2011-08 |
CYP2B6 Polymorphisms Influence the Plasma Concentration and Clearance of the Methadone S-Enantiomer
|
(Wang SC);(Ho IK);(Tsou HH);(Tian JN);(Hsiao CF);(Chen CH);(Tan HK);(Lin L);(Wu CS);(Su LW);黃介良(Chieh-Liang Huang);(Yang YH);(Liu ML);(Lin KM);(Chen CY);(Liu SC);(Wu HY);(Chan HW);(sai MH);(Lin PS);(Liu YL)* |
| 臺大學術典藏 |
2020-11-04T09:17:20Z |
CYP2B6 polymorphisms influence the plasma concentration and clearance of the methadone S-enantiomer
|
Wang S.-C.; Ho I.-K.; Tsou H.-H.; Tian J.-N.; Hsiao C.-F.; Chen C.-H.; Tan H.K.-L.; Lin L.; CHI-SHIN WU; Su L.-W.; Huang C.-L.; Yang Y.-H.; Liu M.-L.; Lin K.-M.; Chen C.-Y.; Liu S.C.; Wu H.-Y.; Chan H.-W.; Tsai M.-H.; Lin P.-S.; Liu Y.-L. |
| 國立成功大學 |
2008-08 |
CYP2C19 genotypes and Helicobacter pylori eradication
|
Sheu, Bor-Shyang; Fock, Kwong-Ming |
| 國立成功大學 |
2012-01 |
CYP2C19 genotypes determine the efficacy of on-demand therapy of pantoprazole for reflux esophagitis as Los-Angeles grades C and D
|
Sheu, Bor-Shyang; Cheng, Hsiu-Chi; Yeh, Yi-Chun; Chang, Wei-Lun |
| 國立臺灣大學 |
2010 |
Cyp2c19 Genotypes in the Pharmacokinetics/Pharmacodynamics of Proton Pump Inhibitor-Based Therapy of Helicobacter Pylori Infection
|
楊智欽; 林君榮; YANG, JYH-CHIN; LIN, CHUN-JUNG |
| 臺大學術典藏 |
2018-09-10T08:02:38Z |
CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection
|
Yang, J.-C.;Lin, C.-J.; CHUN-JUNG LIN; JYH-CHIN YANG |
| 臺大學術典藏 |
2021-06-04T03:09:19Z |
CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection
|
Yang J.-C.; CHUN-JUNG LIN |
| 臺大學術典藏 |
2022-03-04T08:22:49Z |
CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection
|
JYH-CHIN YANG; Lin C.-J. |
| 臺大學術典藏 |
2021-05-27T02:50:13Z |
CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection
|
JYH-CHIN YANG; Lin C.-J. |
